drugset / Trial / NCT01206660

Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis

NCT01206660 ↗

Phase 3 Completed 120 enrolled Sun Pharmaceutical Industries, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The objective of this study is to demonstrate that desoximetasone 0.25% topical spray is effective for the treatment of patients with moderate to severe plaque psoriasis.

Timeline

Start
2010-08
Primary completion
2010-12
Completion
2011-01

Outcome

Met primary endpoint

registry analysis (superiority or other test); Desoximetasone Spray 0.25% vs Placebo; p <0.0001; t-test, 2 sided NCT01206660 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Desoximetasone Small molecule 0.25 % Topical

Indications